IFN-α has proven anti-tumor effect in several tumor types, such as hairy cell leukemia and renal cell cancer, and has been used in osteosarcoma patients as adjuvant treatment in Scandinavia since the 1970s [5–7]. The gene discussed is IFNA1; the disease is neoplasm.